- Published: Wednesday, 08 April 2020 09:16
Stem Cell Therapy and ARDS
Acute respiratory distress syndrome, or ARDS, was a relatively rare condition until the advent of the novel coronavirus and COVID-19. Prior to the global pandemic of 2020, ARDS affected fewer than 200,000 individuals per year, but that number has risen significantly.
What Is ARDS?
ARDS is an acronym for acute respiratory distress syndrome. It’s also known as acute lung injury and noncardiac pulmonary edema. The National Heart, Lung, and Blood Institute defines it as,
“a serious lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury. In ARDS, fluid builds up inside the tiny air sacs of the lungs, and the surfactant breaks down. Surfactant is a foamy substance that keeps the lungs fully expanded so that a person can breathe.”